TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Hormone replacement therapy following treatment of gynaecological malignancies
Key Statistics
- ~21,000 — UK women DX gynae malignancy, 2015
- 30–40% — Present pre-/peri-menopausal
- 5 — Cancer sites covered (endometrial, ovarian, cervical, vulval, vaginal)
Don't-miss facts
-
~21,000 UK women/year diagnosed with gynaecological malignancy (2015); 30–40% pre-/peri-menopausal at diagnosis
-
Cancer treatment (surgery/chemo/radiotherapy) in younger women can cause an induced menopause
-
HRT safety must be judged by cancer type, stage and grade – covers endometrial, ovarian, cervical, vulval, vaginal cancers
-
Most UK units lack menopause specialist access; do not withhold HRT reflexively – know true contraindications
-
Non-hormonal alternatives have a role where HRT is contraindicated or declined
-
Caveat: these notes are abstract-level only – verify against full TOG article for site-specific evidence and regimens
Scope of article
Endometrial Ovarian Cervical Vulval Vaginal
Abbreviation Key
- HRT — hormone replacement therapy
- UK — United Kingdom
- TOG — The Obstetrician & Gynaecologist could not be retrieved (Wiley institutional access unavailable); verify against the original TOG article for additional detail.
Source: Richardson A, Ayres J, Cust M, Phillips A. Hormone replacement therapy following treatment of gynaecological malignancies. The Obstetrician & Gynaecologist 2019;21:291–298. doi:10.1111/tog.12607
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).